Related references
Note: Only part of the references are listed.Abbreviated-protocol screening MRI vs. complete-protocol diagnostic MRI for detection of hepatocellular carcinoma in patients with cirrhosis: An equivalence study using LI-RADS v2018
Gaurav Khatri et al.
JOURNAL OF MAGNETIC RESONANCE IMAGING (2020)
Real-World Effectiveness From the Asia Pacific Rim Liver Consortium for HBV Risk Score for the Prediction of Hepatocellular Carcinoma in Chronic Hepatitis B Patients Treated With Oral Antiviral Therapy
Hwai- Yang et al.
JOURNAL OF INFECTIOUS DISEASES (2020)
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
Richard S. Finn et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Epidemiology and surveillance for hepatocellular carcinoma: New trends
Amit G. Singal et al.
JOURNAL OF HEPATOLOGY (2020)
mRECIST for HCC: Performance and novel refinements
Josep M. Llovet et al.
JOURNAL OF HEPATOLOGY (2020)
Milestones in the pathogenesis and management of primary liver cancer
Jean-Charles Nault et al.
JOURNAL OF HEPATOLOGY (2020)
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
Richard S. Finn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Tumour-intrinsic resistance to immune checkpoint blockade
Anusha Kalbasi et al.
NATURE REVIEWS IMMUNOLOGY (2020)
Hepatocellular Carcinoma Detection by Plasma Methylated DNA: Discovery, Phase I Pilot, and Phase II Clinical Validation
John B. Kisiel et al.
HEPATOLOGY (2019)
Detection of early-stage hepatocellular carcinoma in asymptomatic HBsAg-seropositive individuals by liquid biopsy
Chunfeng Qu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
Genome-wide copy number alteration and VEGFA amplification of circulating cell-free DNA as a biomarker in advanced hepatocellular carcinoma patients treated with Sorafenib
Chung Ryul Oh et al.
BMC CANCER (2019)
Surveillance for Hepatocellular Carcinoma: Current Best Practice and Future Direction
Fasiha Kanwal et al.
GASTROENTEROLOGY (2019)
2018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma
Joong-Won Park et al.
GUT AND LIVER (2019)
Pravastatin combination with sorafenib does not improve survival in advanced hepatocellular carcinoma
Jean-Louis Jouve et al.
JOURNAL OF HEPATOLOGY (2019)
Platelet GPIbα is a mediator and potential interventional target for NASH and subsequent liver cancer
Mohsen Malehmir et al.
NATURE MEDICINE (2019)
Hepatocellular Carcinoma
Augusto Villanueva
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion A Randomized Clinical Trial
MinKe He et al.
JAMA ONCOLOGY (2019)
The Labyrinth of Product Development and Regulatory Approvals in Liquid Biopsy Diagnostics
Federico M. Goodsaid
CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2019)
Clinical practice guidelines for hepatocellular carcinoma: The Japan Society of Hepatology 2017 (4th JSH-HCC guidelines) 2019 update
Norihiro Kokudo et al.
HEPATOLOGY RESEARCH (2019)
Randomized trials and endpoints in advanced HCC: Role of PFS as a surrogate of survival
Josep M. Llovet et al.
JOURNAL OF HEPATOLOGY (2019)
β-Catenin Activation Promotes Immune Escape and Resistance to Anti-PD-1 Therapy in Hepatocellular Carcinoma
Marina Ruiz de Galarreta et al.
CANCER DISCOVERY (2019)
Vaccinia-based oncolytic immunotherapy Pexastimogene Devacirepvec in patients with advanced hepatocellular carcinoma after sorafenib failure: a randomized multicenter Phase IIb trial (TRAVERSE)
M. Moehler et al.
ONCOIMMUNOLOGY (2019)
Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trial
Philippe Merle et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2019)
Lipophilic Statins and Risk for Hepatocellular Carcinoma and Death in Patients With Chronic Viral Hepatitis: Results From a Nationwide Swedish Population
Tracey G. Simon et al.
ANNALS OF INTERNAL MEDICINE (2019)
Microwave ablation compared with radiofrequency ablation for treatment of hepatocellular carcinoma and liver metastases: a systematic review and meta-analysis
Mrudula B. Glassberg et al.
ONCOTARGETS AND THERAPY (2019)
First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma
Richard D. Kim et al.
CANCER DISCOVERY (2019)
Assessment of Treatment With Sorafenib Plus Doxorubicin vs Sorafenib Alone in Patients With Advanced Hepatocellular Carcinoma Phase 3 CALGB 80802 Randomized Clinical Trial
Ghassan K. Abou-Alfa et al.
JAMA ONCOLOGY (2019)
Integrated Proteogenomic Characterization of HBV-Related Hepatocellular Carcinoma
Qiang Gao et al.
CELL (2019)
Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next-Generation Sequencing for Matching Patients to Targeted and Immune Therapies
James J. Harding et al.
CLINICAL CANCER RESEARCH (2019)
Immune Exclusion-Wnt/CTNNB1 Class Predicts Resistance to Immunotherapies in HCC
Roser Pinyol et al.
CLINICAL CANCER RESEARCH (2019)
Targeted and Immune-Based Therapies for Hepatocellular Carcinoma
Tim F. Greten et al.
GASTROENTEROLOGY (2019)
Initial results of pulmonary resection after neoadjuvant nivolumab in patients with resectable non-small cell lung cancer
Matthew J. Bott et al.
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY (2019)
Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial
Andrew X. Zhu et al.
LANCET ONCOLOGY (2019)
AASLD guidelines for the treatment of hepatocellular carcinoma
Julie K. Heimbach et al.
HEPATOLOGY (2018)
Phase III randomized study of second line ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma
G. K. Abou-Alfa et al.
ANNALS OF ONCOLOGY (2018)
Phase II Studies with Refametinib or Refametinib plus Sorafenib in Patients with RAS-Mutated Hepatocellular Carcinoma
Ho Yeong Lim et al.
CLINICAL CANCER RESEARCH (2018)
Surveillance Imaging and Alpha Fetoprotein for Early Detection of Hepatocellular Carcinoma in Patients With Cirrhosis: A Meta-analysis
Kristina Tzartzeva et al.
GASTROENTEROLOGY (2018)
Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases
Jorge A. Marrero et al.
HEPATOLOGY (2018)
SIRveNIB: Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma
Pierce K. H. Chow et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy
F. Stephen Hodi et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
The impact of combining Selective Internal Radiation Therapy (SIRT) with Sorafenib on overall survival in patients with advanced hepatocellular carcinoma: The Soramic trial palliative cohort
J. Ricke et al.
JOURNAL OF HEPATOLOGY (2018)
Targets for immunotherapy of liver cancer
Tim F. Greten et al.
JOURNAL OF HEPATOLOGY (2018)
Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial
Richard S. Finn et al.
JOURNAL OF HEPATOLOGY (2018)
Percutaneous treatment of hepatocellular carcinoma: State of the art and innovations
Jean-Charles Nault et al.
JOURNAL OF HEPATOLOGY (2018)
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
Masatoshi Kudo et al.
LANCET (2018)
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
Andrew X. Zhu et al.
LANCET ONCOLOGY (2018)
Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study
Lorenza Rimassa et al.
LANCET ONCOLOGY (2018)
Metformin and risk of hepatocellular carcinoma in patients with type 2 diabetes
Chin-Hsiao Tseng
LIVER INTERNATIONAL (2018)
Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
Dal Fukurnura et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
HEALTH POLICY Reinforcing the social compromise of accelerated approval
Bishal Gyawali et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
G. K. Abou-Alfa et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
A pilot study of ultra-deep targeted sequencing of plasma DNA identifies driver mutations in hepatocellular carcinoma
Ismail Labgaa et al.
ONCOGENE (2018)
Guidelines for Diagnosis and Treatment of Primary Liver Cancer in China (2017 Edition)
Jian Zhou et al.
LIVER CANCER (2018)
Defining the Most Appropriate Primary End Point in Phase 2 Trials of Immune Checkpoint Inhibitors for Advanced Solid Cancers A Systematic Review and Meta-analysis
Georgia Ritchie et al.
JAMA ONCOLOGY (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
A phase 1b trial of lenvatinib (LEN) plus pembrolizumab (PEM) in patients (pts) with unresectable hepatocellular carcinoma (uHCC).
Masafumi Ikeda et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Molecular therapies and precision medicine for hepatocellular carcinoma
Josep M. Llovet et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Differences in hepatocellular carcinoma risk, predictors and trends over time according to etiology of cirrhosis
George N. Ioannou et al.
PLOS ONE (2018)
Proposal of Primary Endpoints for TACE Combination Trials with Systemic Therapy: Lessons Learned from 5 Negative Trials and the Positive TACTICS Trial
Masatoshi Kudo
LIVER CANCER (2018)
LBA27A randomized multicentered phase II study to evaluate SHR-1210 (PD-1 antibody) in subjects with advanced hepatocellular carcinoma (HCC) who failed or intolerable to prior systemic treatment
S K Qin et al.
ANNALS OF ONCOLOGY (2018)
Detection and Analysis of Circulating Epithelial Cells in Liquid Biopsies From Patients With Liver Disease
Irun Bhan et al.
GASTROENTEROLOGY (2018)
Risk of Hepatocellular Cancer in Patients With Non-Alcoholic Fatty Liver Disease
Fasiha Kanwal et al.
GASTROENTEROLOGY (2018)
Application of Cell-free DNA Analysis to Cancer Treatment
Ryan B. Corcoran et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Association Between Aspirin Use and Risk of Hepatocellular Carcinoma
Tracey G. Simon et al.
JAMA ONCOLOGY (2018)
Orantinib versus placebo combined with transcatheter arterial chemoembolisation in patients with unresectable hepatocellular carcinoma (ORIENTAL): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study
Masatoshi Kudo et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2018)
An Assessment of Benefits and Harms of Hepatocellular Carcinoma Surveillance in Patients With Cirrhosis
Omair Atiq et al.
HEPATOLOGY (2017)
Hepatocellular Carcinoma: Therapeutic Guidelines and Medical Treatment
Masatoshi Kudo et al.
LIVER CANCER (2017)
Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features
Daniela Sia et al.
GASTROENTEROLOGY (2017)
Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update
Masao Omata et al.
HEPATOLOGY INTERNATIONAL (2017)
Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC
Riccardo Lencioni et al.
JOURNAL OF HEPATOLOGY (2017)
Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma
Austin G. Duffy et al.
JOURNAL OF HEPATOLOGY (2017)
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
Jordi Bruix et al.
LANCET (2017)
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
Anthony B. El-Khoueiry et al.
LANCET (2017)
Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial
Valerie Vilgrain et al.
LANCET ONCOLOGY (2017)
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
Lesley Seymour et al.
LANCET ONCOLOGY (2017)
mRECIST to predict survival in advanced hepatocellular carcinoma: Analysis of two randomised phase II trials comparing nintedanib vs sorafenib
Tim Meyer et al.
LIVER INTERNATIONAL (2017)
Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma
Rui-hua Xu et al.
NATURE MATERIALS (2017)
Ramucirumab as Second-Line Treatment in Patients With Advanced Hepatocellular Carcinoma Analysis of REACH Trial Results by Child-Pugh Score
Andrew X. Zhu et al.
JAMA ONCOLOGY (2017)
Immuno-oncology Trial Endpoints: Capturing Clinically Meaningful Activity
Valsamo Anagnostou et al.
CLINICAL CANCER RESEARCH (2017)
Proliferation Markers Are Associated with MET Expression in Hepatocellular Carcinoma and Predict Tivantinib Sensitivity In Vitro
Sandra Rebouissou et al.
CLINICAL CANCER RESEARCH (2017)
Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial
Tim Meyer et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2017)
Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma
Adrian Ally et al.
CELL (2017)
Changes in the Glycosylation of Kininogen and the Development of a Kininogen-Based Algorithm for the Early Detection of HCC
Mengjun Wang et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2017)
Liquid biopsies come of age: towards implementation of circulating tumour DNA
Jonathan C. M. Wan et al.
NATURE REVIEWS CANCER (2017)
Precision oncology: A new era of cancer clinical trials
Lindsay A. Renfro et al.
CANCER LETTERS (2017)
Transarterial chemo-embolisation of hepatocellular carcinoma: impact of liver function and vascular invasion
Imam Waked et al.
BRITISH JOURNAL OF CANCER (2017)
Treatment of Liver Tumors with Lipiodol TACE: Technical Recommendations from Experts Opinion
Thierry de Baere et al.
CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY (2016)
Lipiodol Transarterial Chemoembolization for Hepatocellular Carcinoma: A Systematic Review of Efficacy and Safety Data
Riccardo Lencioni et al.
HEPATOLOGY (2016)
Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial
Riccardo Lencioni et al.
JOURNAL OF HEPATOLOGY (2016)
A multicentre comparison between Child Pugh and Albumin-Bilirubin scores in patients treated with sorafenib for Hepatocellular Carcinoma
Julien Edeline et al.
LIVER INTERNATIONAL (2016)
Palbociclib and Letrozole in Advanced Breast Cancer
Richard S. Finn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Blood-Based Analysis of Circulating Cell-Free DNA and Tumor Cells for Early Cancer Detection
Klaus Pantel
PLOS MEDICINE (2016)
Hepatocellular carcinoma
Josep M. Llovet et al.
NATURE REVIEWS DISEASE PRIMERS (2016)
Response Rate as a Regulatory End Point in Single-Arm Studies of Advanced Solid Tumors
Geoffrey R. Oxnard et al.
JAMA ONCOLOGY (2016)
Global Cancer Statistics, 2012
Lindsey A. Torre et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2015)
Subclassification of BCLC B Stage Hepatocellular Carcinoma and Treatment Strategies: Proposal of Modified Bolondi's Subclassification (Kinki Criteria)
Masatoshi Kudo et al.
DIGESTIVE DISEASES (2015)
Downstaging of hepatocellular cancer before liver transplant: Long-term outcome compared to tumors within Milan criteria
Francis Y. Yao et al.
HEPATOLOGY (2015)
The role of hepatic resection in the treatment of hepatocellular cancer
Sasan Roayaie et al.
HEPATOLOGY (2015)
SEARCH: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Sorafenib Plus Erlotinib in Patients With Advanced Hepatocellular Carcinoma
Andrew X. Zhu et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Linifanib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: Results of a Randomized Phase III Trial
Calin Cainap et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approach-The ALBI Grade
Philip J. Johnson et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial
Andrew X. Zhu et al.
LANCET ONCOLOGY (2015)
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial
Jordi Bruix et al.
LANCET ONCOLOGY (2015)
Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study
Joong-Won Park et al.
LIVER INTERNATIONAL (2015)
Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets
Kornelius Schulze et al.
NATURE GENETICS (2015)
Image-guided ablation of primary liver and renal tumours
David J. Breen et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2015)
The future of immune checkpoint therapy
Padmanee Sharma et al.
SCIENCE (2015)
The Strength of Association Between Surrogate End Points and Survival in Oncology A Systematic Review of Trial-Level Meta-analyses
Vinay Prasad et al.
JAMA INTERNAL MEDICINE (2015)
Safety and efficacy of ipilimumab to treat advanced melanoma in the setting of liver transplantation
Rita E. Morales et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2015)
Peretinoin after curative therapy of hepatitis C-related hepatocellular carcinoma: a randomized double-blind placebo-controlled study
Kiwamu Okita et al.
JOURNAL OF GASTROENTEROLOGY (2015)
EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
et al.
JOURNAL OF HEPATOLOGY (2015)
Prognostic Relevance of Objective Response According to EASL Criteria and mRECIST Criteria in Hepatocellular Carcinoma Patients Treated with Loco-Regional Therapies: A Literature-Based Meta-Analysis
Bruno Vincenzi et al.
PLOS ONE (2015)
Quality of life after surgical resection compared with radiofrequency ablation for small hepatocellular carcinomas
G. Huang et al.
BRITISH JOURNAL OF SURGERY (2014)
The Detection of Hepatocellular Carcinoma Using a Prospectively Developed and Validated Model Based on Serological Biomarkers
Philip J. Johnson et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2014)
Brivanib as Adjuvant Therapy to Transarterial Chemoembolization in Patients With Hepatocellular Carcinoma: A Randomized Phase III Trial
Masatoshi Kudo et al.
HEPATOLOGY (2014)
Effect of Everolimus on Survival in Advanced Hepatocellular Carcinoma After Failure of Sorafenib The EVOLVE-1 Randomized Clinical Trial
Andrew X. Zhu et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2014)
American Society of Clinical Oncology Perspective: Raising the Bar for Clinical Trials by Defining Clinically Meaningful Outcomes
Lee M. Ellis et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Trans-ancestry mutational landscape of hepatocellular carcinoma genomes
Yasushi Totoki et al.
NATURE GENETICS (2014)
Treatment of intermediate-stage hepatocellular carcinoma
Alejandro Fomer et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2014)
Alternative Response Criteria (Choi, European Association for the Study of the Liver, and Modified Response Evaluation Criteria in Solid Tumors [RECIST]) Versus RECIST 1.1 in Patients With Advanced Hepatocellular Carcinoma Treated With Sorafenib
Maxime Ronot et al.
ONCOLOGIST (2014)
A simple prognostic scoring system for patients receiving transarterial embolisation for hepatocellular cancer
L. Kadalayil et al.
ANNALS OF ONCOLOGY (2013)
A randomised phase II/III trial of 3-weekly cisplatin-based sequential transarterial chemoembolisation vs embolisation alone for hepatocellular carcinoma
T. Meyer et al.
BRITISH JOURNAL OF CANCER (2013)
New Data Supporting Modified RECIST (mRECIST) for Hepatocellular Carcinoma
Riccardo Lencioni
CLINICAL CANCER RESEARCH (2013)
Developing a Common Language for Tumor Response to Immunotherapy: Immune-Related Response Criteria Using Unidimensional Measurements
Mizuki Nishino et al.
CLINICAL CANCER RESEARCH (2013)
Increased Quality of Life Among Hepatocellular Carcinoma Patients Treated With Radioembolization, Compared With Chemoembolization
Riad Salem et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2013)
A review of phase II trial designs for initial marker validation
Sumithra J. Mandrekar et al.
CONTEMPORARY CLINICAL TRIALS (2013)
Resection of hepatocellular cancer ≤2 cm: Results from two Western centers
Sasan Roayaie et al.
HEPATOLOGY (2013)
Postprogression Survival of Patients With Advanced Hepatocellular Carcinoma: Rationale for Second-Line Trial Design
Maria Reig et al.
HEPATOLOGY (2013)
Yttrium 90 Radioembolization for the Treatment of Hepatocellular Carcinoma: Biological Lessons, Current Challenges, and Clinical Perspectives
Riad Salem et al.
HEPATOLOGY (2013)
Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study
Philip J. Johnson et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Randomized, Multicenter, Open-Label Study of Oxaliplatin Plus Fluorouracil/Leucovorin Versus Doxorubicin As Palliative Chemotherapy in Patients With Advanced Hepatocellular Carcinoma From Asia
Shukui Qin et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Brivanib in Patients With Advanced Hepatocellular Carcinoma Who Were Intolerant to Sorafenib or for Whom Sorafenib Failed: Results From the Randomized Phase III BRISK-PS Study
Josep M. Llovet et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Sunitinib Versus Sorafenib in Advanced Hepatocellular Cancer: Results of a Randomized Phase III Trial
Ann-Lii Cheng et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C
Bruno Sangro et al.
JOURNAL OF HEPATOLOGY (2013)
Comparative efficacy of sorafenib versus best supportive care in recurrent hepatocellular carcinoma after liver transplantation: A case-control study
Carlo Sposito et al.
JOURNAL OF HEPATOLOGY (2013)
Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer
Jeong Heo et al.
NATURE MEDICINE (2013)
Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma
Julien Edeline et al.
CANCER (2012)
Plasma Biomarkers as Predictors of Outcome in Patients with Advanced Hepatocellular Carcinoma
Josep M. Llovet et al.
CLINICAL CANCER RESEARCH (2012)
International cross-cultural field validation of an European Organization for Research and Treatment of Cancer questionnaire module for patients with primary liver cancer, the European Organization for Research and Treatment of Cancer quality-of-life questionnaire HCC18
Wei-Chu Chie et al.
HEPATOLOGY (2012)
Assumptions of Expected Benefits in Randomized Phase III Trials Evaluating Systemic Treatments for Cancer
Hui K. Gan et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2012)
Analysis of Overall Level of Evidence Behind Infectious Diseases Society of America Practice Guidelines
Dong Heun Lee et al.
ARCHIVES OF INTERNAL MEDICINE (2011)
Management of Hepatocellular Carcinoma: An Update
Jordi Bruix et al.
HEPATOLOGY (2011)
EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolisation
Roopinder Gillmore et al.
JOURNAL OF HEPATOLOGY (2011)
Prospective Randomized Study of Doxorubicin-Eluting-Bead Embolization in the Treatment of Hepatocellular Carcinoma: Results of the PRECISION V Study
Johannes Lammer et al.
CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY (2010)
Response Evaluation Criteria in Cancer of the Liver (RECICL) proposed by the Liver Cancer Study Group of Japan (2009 Revised Version)
Masatoshi Kudo et al.
HEPATOLOGY RESEARCH (2010)
Anaplastic Lymphoma Kinase Inhibition in Non-Small-Cell Lung Cancer
Eunice L. Kwak et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma
Riccardo Lencioni et al.
SEMINARS IN LIVER DISEASE (2010)
Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
Jedd D. Wolchok et al.
CLINICAL CANCER RESEARCH (2009)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Systematic Review of Randomized Trials for Hepatocellular Carcinoma Treated with Percutaneous Ablation Therapies
Yun Ku Cho et al.
HEPATOLOGY (2009)
Clinical Trial Designs for Predictive Biomarker Validation: Theoretical Considerations and Practical Challenges
Sumithra J. Mandrekar et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Use of Archived Specimens in Evaluation of Prognostic and Predictive Biomarkers
Richard M. Simon et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
Ann-Lii Cheng et al.
LANCET ONCOLOGY (2009)
Genomic advances and their impact on clinical trial design
Sumithra J. Mandrekar et al.
GENOME MEDICINE (2009)
Adjuvant intra-arterial iodine-131-labeled lipiodol for resectable hepatocellular carcinoma - A prospective randomized trial - Update on 5-year and 10-year survival
Wan Yee Lau et al.
ANNALS OF SURGERY (2008)
Pivotal Evaluation of the Accuracy of a Biomarker Used for Classification or Prediction: Standards for Study Design
Margaret S. Pepe et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
Design and endpoints of clinical trials in hepatocellular carcinoma
Josep M. Llovet et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
Sorafenib in advanced hepatocellular carcinoma
Josep M. Llovet et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
Brian J. Druker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Surrogate threshold effect: An alternative measure for meta-analytic surrogate endpoint validation
Tomasz Burzykowski et al.
PHARMACEUTICAL STATISTICS (2006)
Reporting of noninferiority and equivalence randomized trials - An extension of the CONSORT Statement
G Piaggio et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Systematic review: evidence-based management of hepatocellular carcinoma - an updated analysis of randomized controlled trials
P. M. Lopez et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2006)
A randomized phase III study of doxorubicin versus cisplatin/interferon α-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma
W Yeo et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
Development of a questionnaire module to supplement the EORTC QLQ-C30 to assess quality of life in patients with hepatocellular carcinoma, the EORTC QLQ-HCC18
JM Blazeby et al.
EUROPEAN JOURNAL OF CANCER (2004)
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
TJ Lynch et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival
JM Llovet et al.
HEPATOLOGY (2003)
High-dose tamoxifen in the treatment of inoperable hepatocellular carcinoma: A multicenter randomized controlled trial
PKH Chow et al.
HEPATOLOGY (2002)
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
GD Demetri et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma:: a randomised controlled trial
JM Llovet et al.
LANCET (2002)
Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma
CM Lo et al.
HEPATOLOGY (2002)
The revised CONSORT statement for reporting randomized trials: Explanation and elaboration
DG Altman et al.
ANNALS OF INTERNAL MEDICINE (2001)
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
DJ Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial
T Takayama et al.
LANCET (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Share Paper
